Clinical Trials Directory

Trials / Completed

CompletedNCT05372549

Correlation of Oxidative Stress and Oocyte Quality in Fertility Preservation

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
179 (actual)
Sponsor
Clinique Ovo · Industry
Sex
Female
Age
18 Years – 37 Years
Healthy volunteers
Not accepted

Summary

Whether it is for oncology or personal reasons, fertility preservation allows participants to preserve their oocytes (eggs) at their current age and condition for a better chance of having a baby in the future. In order to proceed with fertility preservation, participants will need to undergo in vitro fertilization (IVF), which is standard practice, and take stimulation medication to stimulate production of more follicles. The combination of both Rekovelle and Menopur for fertility preservation may increase ovarian response to stimulation and increase the number of oocytes retrieved to give better chances of embryos once the oocytes will be fertilized. The goal in this study is to understand the effect of oxydative stress on the quality of oocytes. For the purpose of the study and to evaluate this connection, serum levels of oxidative stress and cf-DNA in your blood will be measured. Oocyte quality will also be assessed with Magenta, a prediction tool utilizing artificial intelligence (AI). This method is non-invasive and has no risks on the oocytes.

Conditions

Interventions

TypeNameDescription
OTHEROxidative stressOxidative stress occurs as soon as there is an imbalance between pro- / antioxidants, and molecules exhibiting antioxidant properties are at the forefront of fertility treatment and preservation. Oxidated stress will be measured by blood sample
OTHERcf-DNAcfDNA, extracted from blood plasma in samples collected will uncover the potential role of cfDNA as a stress signal released in response to oxidative stress
OTHERMAGENTA AINon-invasive technique analyzing images of oocytes that can differentiate oocytes with a higher reproductive potential reflective of their quality

Timeline

Start date
2022-06-01
Primary completion
2024-12-18
Completion
2025-01-03
First posted
2022-05-12
Last updated
2025-03-20

Locations

3 sites across 1 country: Canada

Source: ClinicalTrials.gov record NCT05372549. Inclusion in this directory is not an endorsement.